Keywords: Adolor, GlaxoSmithKline, Entereg, Bowel dysfunction

Adolor to pay GSK $25 million plus royalties to reacquire Entereg rights

Article | 16 June 2011

Print This

USA-based Adolor Corp (NasdaqGM: ADLR) has reached agreement with UK pharma giant GlaxoSmithKline (LSE: GSK) to reacquire all rights to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in